Close Menu

CastPCR

The results, if confirmed further, could help pick out unresponsive patients early, opening up other therapeutic options for them.

Cynvenio Biosystems said this week that it expects to gain CLIA certification in the next few weeks for its circulating tumor cell technology.

By Ben Butkus
Life Technologies this week announced the expansion of its TaqMan Mutation Detection Assays based on competitive allele-specific TaqMan, or Cast, PCR technology.

The mutation detection assays for KRAS, BRAF, and EGFR genes are based on competitive allele-specific TaqMan PCR. The company claims the assays are sensitive enough to detect single mutant molecules in a background of 1 million normal copies.

Initial unpublished data from studies employing the method, competitive allele-specific TaqMan PCR, suggest that it can detect single rare mutant alleles in up to a million wild-type sequences with a high degree of specificity.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.